JP2006524117A - 手術後に迅速に自らシールする能力を持つ動静脈移植片 - Google Patents
手術後に迅速に自らシールする能力を持つ動静脈移植片 Download PDFInfo
- Publication number
- JP2006524117A JP2006524117A JP2006513212A JP2006513212A JP2006524117A JP 2006524117 A JP2006524117 A JP 2006524117A JP 2006513212 A JP2006513212 A JP 2006513212A JP 2006513212 A JP2006513212 A JP 2006513212A JP 2006524117 A JP2006524117 A JP 2006524117A
- Authority
- JP
- Japan
- Prior art keywords
- layer
- graft
- outer layer
- self
- inner layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001356 surgical procedure Methods 0.000 title description 2
- 239000004744 fabric Substances 0.000 claims abstract description 38
- 238000007789 sealing Methods 0.000 claims abstract description 27
- 229920000642 polymer Polymers 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 4
- 239000000835 fiber Substances 0.000 claims description 22
- 239000007943 implant Substances 0.000 claims description 21
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 16
- -1 polyethylene tetraphthalate Polymers 0.000 claims description 10
- 229920000728 polyester Polymers 0.000 claims description 7
- 229920002379 silicone rubber Polymers 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 235000010410 calcium alginate Nutrition 0.000 claims description 4
- 229960002681 calcium alginate Drugs 0.000 claims description 4
- 239000000648 calcium alginate Substances 0.000 claims description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 229920001971 elastomer Polymers 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000009940 knitting Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 5
- 239000004810 polytetrafluoroethylene Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 238000001631 haemodialysis Methods 0.000 description 4
- 230000000322 hemodialysis Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000009998 heat setting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 238000009941 weaving Methods 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229940019931 silver phosphate Drugs 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/075—Stent-grafts the stent being loosely attached to the graft material, e.g. by stitching
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
Abstract
【解決手段】上記布地の外層は上記内層の周りに同心的に配置されている。さらに、中間の自ずからシールする層が上記内層と外層の間に同心的に配置されている。上記の自ずからシールする層は生体適合性のポリマーを含んでいる。
Description
もう一つの態様において、生体適合性ポリマー層50は生分解性である。中間層50に有用な望ましい生分解性素材にはトリメチレンカーボネート、ポリエチレングリコール、ポリプロピレングリコール、ポリラクチド/ポリグリコリドポリマー、コラーゲン及びアルギネートが含まれるが、これらに限定はされない。
4種類のePTFE移植片が編みカバーを持つePTFE移植片と比較され、編みカバーが結果として縫合線の維持強度の増大となるか否かが決定された。縫合線の維持力とは、試料の人工器官から縫合線を引き離すのに必要な力、或いは人工器官の壁の不作動を引き起こすに必要な力を意味する。
各人工器官を長軸に直角に切れ目を入れた(cut normal to the long axis)。縫合線を人工器官の一つの壁を通して引張った人工器官の末端から2mmのところに入れて半ループを形成した。縫合線を一分間に150mmの速度で引っ張った。人工器官を通して縫合線を引っ張るのに要する力或いは人工器官の壁の不全(崩壊)を引き起こすのに要する力が記録された(グラムで測定)。すべてのテストは医療器具推進協会の必要条件に従って行われた。
人工器官を長軸に対して45度で切れ目を入れた。縫合線を切断部の基部(ヒール、かかと)に入れた。人工器官を通して縫合線を引っ張る力或いは人工器官の壁の不全(崩壊)を引き起こすに要する力を各試料人工器官に対してグラムで記録した。
加えて、上記の移植片5個の耐久性について反復穿刺テストを用いて検討した。このテストの意図は、透析使用を模擬して反復穿刺した後、人工器官の強度を決定することにある。試料は反復穿刺され、次いで、加圧破裂強度を検査された。
Claims (20)
- 自ずからシールする動靜脈にアクセスする移植片であって、それを通して血液が流れる可能性のある内腔を規定するポリマーの内層と、上記内層の周りに同心的に配置された布地の外層と、及び上記内層と外層の間に同心的に配置され自ずからシールする中間層とを持つチューブからなり、前記の自ずからシールする層は生体適合性ポリマーからなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の自ずからシールする層は、シリコン、ポリウレタン、ポリウレタン‐カーボネート及びそれらの組合せからなるグループから選択されることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の自ずからシールする層はシリコンエラストマーからなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の自ずからシールする層が発泡ポリマーからなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の自ずからシールする層は、さらに、血栓形成阻害剤、抗生物質、抗がん剤、抗ウイルス剤、及びそれらの組合せからなるグループから選ばれた生物治療剤からなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の自ずからシールする層は、さらに、血栓形成阻害剤を含むことを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の布地の外層が、ポリエステル繊維、ポリビニルアルコール繊維、アルギネート繊維、カルシウムアルギネート繊維、及びそれらの組合せからなるグループから選ばれることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の布地の外層がカルシウムを含むことを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の布地の外層がポリエステル繊維からなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記のポリマーの内層がePTFEからなることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記の布地の外層が、編まれた層、織物層、糸の縒り合わせ層、及び不織層からなるグループから選ばれることを特徴とする移植片。
- 請求項1に記載の移植片であって、布地の外層が編まれた層であることを特徴とする移植片。
- 請求項12に記載の移植片であって、上記の編まれた層が撚糸を編んだものであることを特徴とする移植片。
- 請求項13に記載の移植片であって、上記の撚糸ニットがトリコット及びダブルトリコットパターンからなるグループから選ばれることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記外層が上記内層よりも短く、且つ、内層の中心部上に配置されていて、それによって、内層の両端が外層の各末端よりも先に延びることを可能にしていることを特徴とする移植片。
- 請求項1に記載の移植片であって、上記内層が上記外層よりも短く、且つ、上記外層が上記内層の中心部上に配置されていて、それによって、外層の両端が内層の各末端よりも先に延びることを可能にしていることを特徴とする移植片。
- 自ずからシールする動靜脈移植片であって、それを通って血液が流れる可能性のある内腔を規定するポリマーの内層と、上記内層はePTFEからなり、上記内層の周りに同心的に配置されたニットの外層と、上記外層はポリエステルからなり、及び内層と外層の間に同心的に配置された自ずからシールする中間層と、上記自ずからシールする中間層はシリコンエラストマーからなる、を持つチューブからなることを特徴とする移植片。
- 請求項17に記載の移植片であって、上記外層がさらにカルシウムを含むことを特徴とする移植片。
- 請求項17に記載の移植片であって、上記編まれた層は、トリコット及びダブルトリコットからなるグループから選ばれるパターンのものであることを特徴とする移植片。
- 請求項17に記載の移植片であって、ポリエステルがポリエチレンテトラフタレートであることを特徴とする移植片。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/422,118 US7452374B2 (en) | 2003-04-24 | 2003-04-24 | AV grafts with rapid post-operative self-sealing capabilities |
PCT/US2004/012404 WO2004096307A1 (en) | 2003-04-24 | 2004-04-22 | Av grafts with rapid post-operative self-sealing capabilities |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2006524117A true JP2006524117A (ja) | 2006-10-26 |
Family
ID=33298810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006513212A Pending JP2006524117A (ja) | 2003-04-24 | 2004-04-22 | 手術後に迅速に自らシールする能力を持つ動静脈移植片 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7452374B2 (ja) |
EP (1) | EP1631332A1 (ja) |
JP (1) | JP2006524117A (ja) |
CA (1) | CA2525489A1 (ja) |
WO (1) | WO2004096307A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018519893A (ja) * | 2015-06-05 | 2018-07-26 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | テーパ付き低出血性植え込み型人工器官 |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6102884A (en) | 1997-02-07 | 2000-08-15 | Squitieri; Rafael | Squitieri hemodialysis and vascular access systems |
US20050131520A1 (en) * | 2003-04-28 | 2005-06-16 | Zilla Peter P. | Compliant blood vessel graft |
US7998188B2 (en) * | 2003-04-28 | 2011-08-16 | Kips Bay Medical, Inc. | Compliant blood vessel graft |
EP2335648A1 (en) * | 2003-04-28 | 2011-06-22 | Kips Bay Medical, Inc. | Compliant venous graft |
US7762977B2 (en) | 2003-10-08 | 2010-07-27 | Hemosphere, Inc. | Device and method for vascular access |
US7794490B2 (en) * | 2004-06-22 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices with antimicrobial and biodegradable matrices |
WO2006026725A2 (en) | 2004-08-31 | 2006-03-09 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
US8029563B2 (en) * | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
JP2008532573A (ja) * | 2005-01-21 | 2008-08-21 | ジェン 4,リミティド ライアビリティー カンパニー | 二股グラフト及び脚部取付けステント要素を採用したモジュール式ステントグラフト |
US7922761B2 (en) * | 2005-01-25 | 2011-04-12 | Nicast Ltd. | Artificial vascular prosthesis |
WO2006085044A1 (en) | 2005-02-14 | 2006-08-17 | Vascutek Limited | Artificial blood vessel |
US7833263B2 (en) * | 2005-04-01 | 2010-11-16 | Boston Scientific Scimed, Inc. | Hybrid vascular graft reinforcement |
GB0511431D0 (en) * | 2005-06-04 | 2005-07-13 | Vascutek Ltd | Graft |
EP1887968A4 (en) * | 2005-06-08 | 2013-01-23 | Bard Inc C R | TRANSPLANTS AND STENTS WITH INORGANIC BIOKOMPATIBLE CALCIUM SALT |
EP1890641B1 (en) | 2005-06-17 | 2017-04-19 | C.R. Bard, Inc. | Vascular graft with kink resistance after clamping |
JP5280852B2 (ja) | 2005-11-09 | 2013-09-04 | シー・アール・バード・インコーポレーテッド | 放射線不透過性マーカーを有する移植片及びステント植皮 |
US8163002B2 (en) * | 2005-11-14 | 2012-04-24 | Vascular Devices Llc | Self-sealing vascular graft |
US20070167901A1 (en) * | 2005-11-17 | 2007-07-19 | Herrig Judson A | Self-sealing residual compressive stress graft for dialysis |
US8048255B2 (en) * | 2006-01-27 | 2011-11-01 | Medtronic, Inc. | Heatset annuloplasty suture guide |
US20070203564A1 (en) * | 2006-02-28 | 2007-08-30 | Boston Scientific Scimed, Inc. | Biodegradable implants having accelerated biodegradation properties in vivo |
EP2079575B1 (en) | 2006-10-12 | 2021-06-02 | C.R. Bard, Inc. | Methods for making vascular grafts with multiple channels |
KR101719081B1 (ko) | 2007-01-30 | 2017-03-22 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 생분해성 랩 및 그의 용도 |
US8663309B2 (en) | 2007-09-26 | 2014-03-04 | Trivascular, Inc. | Asymmetric stent apparatus and method |
US8226701B2 (en) | 2007-09-26 | 2012-07-24 | Trivascular, Inc. | Stent and delivery system for deployment thereof |
US8066755B2 (en) | 2007-09-26 | 2011-11-29 | Trivascular, Inc. | System and method of pivoted stent deployment |
AU2008308474B2 (en) | 2007-10-04 | 2014-07-24 | Trivascular, Inc. | Modular vascular graft for low profile percutaneous delivery |
US8083789B2 (en) | 2007-11-16 | 2011-12-27 | Trivascular, Inc. | Securement assembly and method for expandable endovascular device |
US8328861B2 (en) | 2007-11-16 | 2012-12-11 | Trivascular, Inc. | Delivery system and method for bifurcated graft |
US20110295181A1 (en) | 2008-03-05 | 2011-12-01 | Hemosphere, Inc. | Implantable and removable customizable body conduit |
CA2716995C (en) * | 2008-03-05 | 2014-11-04 | Hemosphere, Inc. | Vascular access system |
US9468515B2 (en) * | 2009-07-01 | 2016-10-18 | Correx, Inc. | Method and apparatus for effecting a percutaneous aortic valve bypass |
JP2013509258A (ja) | 2009-10-28 | 2013-03-14 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 生体浸食性ラップおよびそのための使用 |
CA2784021C (en) | 2009-12-16 | 2018-03-20 | Neograft Technologies, Inc. | Graft devices and methods of use |
CA2785989A1 (en) | 2009-12-31 | 2011-07-07 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
ES2793478T3 (es) | 2010-03-09 | 2020-11-16 | Solinas Medical Inc | Dispositivos de cierre automático |
US8696738B2 (en) | 2010-05-20 | 2014-04-15 | Maquet Cardiovascular Llc | Composite prosthesis with external polymeric support structure and methods of manufacturing the same |
EP2595695B1 (en) | 2010-07-19 | 2019-02-06 | Neograft Technologies, Inc. | Graft devices and methods of use |
FR2971971B1 (fr) * | 2011-02-24 | 2014-07-11 | Zodiac Automotive Division | Pansement et materiau pour pansement a base de fibres hydrocolloides et de gel silicone |
EP2686033B1 (en) | 2011-03-16 | 2015-05-06 | Duke University | Arteriovenous graft for hemodialysis with puncture-resistant posterior and side walls |
WO2013016349A2 (en) | 2011-07-25 | 2013-01-31 | Neograft Technologies, Inc. | Vessel treatment methods and devices for use in a graft device |
BR112014005094A2 (pt) | 2011-09-06 | 2017-03-28 | Hemosphere Inc | sistema de acesso vascular com conector |
US9155610B2 (en) | 2011-12-13 | 2015-10-13 | Neograft Technologies, Inc. | System and atraumatic mandrel for creating graft devices |
US8992595B2 (en) | 2012-04-04 | 2015-03-31 | Trivascular, Inc. | Durable stent graft with tapered struts and stable delivery methods and devices |
US9498363B2 (en) | 2012-04-06 | 2016-11-22 | Trivascular, Inc. | Delivery catheter for endovascular device |
US9622892B2 (en) | 2012-04-26 | 2017-04-18 | Cook Medical Technologies Llc | Longitudinally reinforced sheath |
CN109998752B (zh) * | 2013-04-13 | 2021-12-24 | 索利纳斯医疗公司 | 自闭合装置以及用于制造和输送自闭合装置的设备和方法 |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
WO2015094514A1 (en) | 2013-12-20 | 2015-06-25 | Cryolife, Inc. | Vascular access system with reinforcement member |
EP3075893B1 (de) * | 2015-04-02 | 2018-09-12 | Karl Mayer Textilmaschinenfabrik GmbH | Wirkware und verfahren zum herstellen einer wirkware |
US10596017B2 (en) | 2016-04-25 | 2020-03-24 | Solinas Medical Inc. | Self-sealing tubular grafts, patches, and methods for making and using them |
US10499920B2 (en) | 2016-11-10 | 2019-12-10 | Merit Medical Systems, Inc. | Anchor device for vascular anastomosis |
US11383072B2 (en) | 2017-01-12 | 2022-07-12 | Merit Medical Systems, Inc. | Methods and systems for selection and use of connectors between conduits |
WO2018140306A1 (en) | 2017-01-25 | 2018-08-02 | Merit Medical Systems, Inc. | Methods and systems for facilitating laminar flow between conduits |
US11026704B2 (en) | 2017-03-06 | 2021-06-08 | Merit Medical Systems, Inc. | Vascular access assembly declotting systems and methods |
US10925710B2 (en) | 2017-03-24 | 2021-02-23 | Merit Medical Systems, Inc. | Subcutaneous vascular assemblies for improving blood flow and related devices and methods |
US11065377B2 (en) | 2017-03-31 | 2021-07-20 | InnAVasc Medical, Inc. | Apparatus and method for cannulation of vascular access graft |
WO2019014444A2 (en) | 2017-07-14 | 2019-01-17 | Merit Medical Systems, Inc. | RELEASABLE CONDUIT FITTINGS |
EP3655086A4 (en) | 2017-07-20 | 2021-04-07 | Merit Medical Systems, Inc. | METHODS AND SYSTEMS FOR COUPLING PIPES |
US11027046B2 (en) | 2017-10-31 | 2021-06-08 | Hothouse Medical Limited | Textile products having selectively applied sealant or coating and method of manufacture |
US11331458B2 (en) | 2017-10-31 | 2022-05-17 | Merit Medical Systems, Inc. | Subcutaneous vascular assemblies for improving blood flow and related devices and methods |
GB201717885D0 (en) | 2017-10-31 | 2017-12-13 | Hothouse Medical Ltd | Prothesis and method of manufacture |
WO2019195353A1 (en) * | 2018-04-04 | 2019-10-10 | Sainess Marius | Low profile self-sealing access port |
CN108517614A (zh) * | 2018-04-13 | 2018-09-11 | 相里海霞 | 一种海藻纤维面料 |
US11925781B2 (en) | 2018-10-30 | 2024-03-12 | InnAVasc Medical, Inc. | Apparatus and method for cannulation of vascular access vessel |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619641A (en) * | 1984-11-13 | 1986-10-28 | Mount Sinai School Of Medicine Of The City University Of New York | Coaxial double lumen anteriovenous grafts |
EP0492481A1 (en) * | 1990-12-27 | 1992-07-01 | Corvita Corporation | Mesh composite graft |
JP2002522155A (ja) * | 1998-08-14 | 2002-07-23 | ボストン・サイエンティフィク・サイムド・インコーポレーテッド | ステント・グラフト・膜体及びその製造方法 |
JP2003511196A (ja) * | 1999-10-15 | 2003-03-25 | エドワーズ ライフサイエンシーズ コーポレイション | 積層型自己封鎖性血管アクセス移植片 |
JP2004538090A (ja) * | 2001-07-23 | 2004-12-24 | ノボバスキュラー インコーポレーテッド | 酸化窒素放出ePTFEコーティング医療用デバイスサンドイッチ |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB567641A (en) | 1942-09-01 | 1945-02-26 | Courtaulds Ltd | Improvements in and relating to the manufacture of alginate threads |
GB571657A (en) | 1942-09-01 | 1945-09-04 | Courtaulds Ltd | Improvements in and relating to the manufacture of alginate threads |
GB568177A (en) | 1943-02-19 | 1945-03-22 | Courtaulds Ltd | Improvements in and relating to the manufacture of threads, filaments, films and thelike from alginates |
GB624987A (en) | 1947-07-22 | 1949-06-20 | Courtaulds Ltd | Improvements in and relating to the manufacture of alginate threads |
US3479670A (en) | 1966-10-19 | 1969-11-25 | Ethicon Inc | Tubular prosthetic implant having helical thermoplastic wrapping therearound |
CA962021A (en) | 1970-05-21 | 1975-02-04 | Robert W. Gore | Porous products and process therefor |
GB1527592A (en) | 1974-08-05 | 1978-10-04 | Ici Ltd | Wound dressing |
US4047252A (en) | 1976-01-29 | 1977-09-13 | Meadox Medicals, Inc. | Double-velour synthetic vascular graft |
JPS6037733B2 (ja) | 1978-10-12 | 1985-08-28 | 住友電気工業株式会社 | 管状臓器補綴材及びその製造方法 |
US4550447A (en) | 1983-08-03 | 1985-11-05 | Shiley Incorporated | Vascular graft prosthesis |
US4718907A (en) | 1985-06-20 | 1988-01-12 | Atrium Medical Corporation | Vascular prosthesis having fluorinated coating with varying F/C ratio |
US4652263A (en) | 1985-06-20 | 1987-03-24 | Atrium Medical Corporation | Elasticization of microporous woven tubes |
US5061276A (en) | 1987-04-28 | 1991-10-29 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
US4892539A (en) | 1988-02-08 | 1990-01-09 | D-R Medical Systems, Inc. | Vascular graft |
IL99296A (en) | 1990-08-28 | 1995-12-08 | Meadox Medicals Inc | A self-supported woven blood vessel implant and its preparation |
US5178630A (en) | 1990-08-28 | 1993-01-12 | Meadox Medicals, Inc. | Ravel-resistant, self-supporting woven graft |
US5163951A (en) | 1990-12-27 | 1992-11-17 | Corvita Corporation | Mesh composite graft |
US5192310A (en) | 1991-09-16 | 1993-03-09 | Atrium Medical Corporation | Self-sealing implantable vascular graft |
US5411550A (en) | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5366504A (en) | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
US5866217A (en) | 1991-11-04 | 1999-02-02 | Possis Medical, Inc. | Silicone composite vascular graft |
DE69325649T2 (de) | 1992-03-13 | 1999-11-18 | Atrium Medical Corp | Gegenstände aus expandiertem fluorpolymer (z. b. polytetrafluorethylen) mit komtrolliert eingestellter porosität, sowie seine herstellung |
US5456711A (en) | 1992-05-15 | 1995-10-10 | Intervascular Inc. | Warp knitted carotid patch having finished selvedged edges |
US5562725A (en) | 1992-09-14 | 1996-10-08 | Meadox Medicals Inc. | Radially self-expanding implantable intraluminal device |
US5628782A (en) | 1992-12-11 | 1997-05-13 | W. L. Gore & Associates, Inc. | Method of making a prosthetic vascular graft |
US5716395A (en) * | 1992-12-11 | 1998-02-10 | W.L. Gore & Associates, Inc. | Prosthetic vascular graft |
GB9306812D0 (en) | 1993-04-01 | 1993-05-26 | Vascutek Ltd | Textile prostheses |
US5370682A (en) | 1993-04-26 | 1994-12-06 | Meadox Medicals, Inc. | Solid woven tubular prosthesis |
US5913894A (en) | 1994-12-05 | 1999-06-22 | Meadox Medicals, Inc. | Solid woven tubular prosthesis |
WO1995009586A1 (en) | 1993-10-01 | 1995-04-13 | Emory University | Self-expanding intraluminal composite prosthesis |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5527353A (en) | 1993-12-02 | 1996-06-18 | Meadox Medicals, Inc. | Implantable tubular prosthesis |
US5591226A (en) | 1995-01-23 | 1997-01-07 | Schneider (Usa) Inc. | Percutaneous stent-graft and method for delivery thereof |
US5741332A (en) | 1995-01-23 | 1998-04-21 | Meadox Medicals, Inc. | Three-dimensional braided soft tissue prosthesis |
US5904967A (en) | 1995-04-27 | 1999-05-18 | Terumo Kabushiki Kaisha | Puncture resistant medical material |
ES2206581T3 (es) | 1995-06-07 | 2004-05-16 | Edwards Lifesciences Corporation | Injerto vascular con cinta de refuerzo y soporte externo. |
US5769882A (en) * | 1995-09-08 | 1998-06-23 | Medtronic, Inc. | Methods and apparatus for conformably sealing prostheses within body lumens |
US5800512A (en) | 1996-01-22 | 1998-09-01 | Meadox Medicals, Inc. | PTFE vascular graft |
US6428571B1 (en) * | 1996-01-22 | 2002-08-06 | Scimed Life Systems, Inc. | Self-sealing PTFE vascular graft and manufacturing methods |
US5728103A (en) | 1996-08-23 | 1998-03-17 | Applied Medical Technology, Inc. | Implantable subcutaneous access device and method of using same |
US5879320A (en) | 1996-12-23 | 1999-03-09 | Cazenave; Craig Richard | Implantable vascular device |
US5957974A (en) | 1997-01-23 | 1999-09-28 | Schneider (Usa) Inc | Stent graft with braided polymeric sleeve |
US6102884A (en) | 1997-02-07 | 2000-08-15 | Squitieri; Rafael | Squitieri hemodialysis and vascular access systems |
DE19720115C2 (de) | 1997-05-14 | 1999-05-20 | Jomed Implantate Gmbh | Stent-Graft |
US5931865A (en) | 1997-11-24 | 1999-08-03 | Gore Enterprise Holdings, Inc. | Multiple-layered leak resistant tube |
EP1032328A1 (en) | 1997-11-25 | 2000-09-06 | Triad Vascular Systems Inc. | Layered endovascular graft |
US6056970A (en) * | 1998-05-07 | 2000-05-02 | Genzyme Corporation | Compositions comprising hemostatic compounds and bioabsorbable polymers |
US6261257B1 (en) | 1998-05-26 | 2001-07-17 | Renan P. Uflacker | Dialysis graft system with self-sealing access ports |
US6261255B1 (en) | 1998-11-06 | 2001-07-17 | Ronald Jay Mullis | Apparatus for vascular access for chronic hemodialysis |
US6440166B1 (en) | 1999-02-16 | 2002-08-27 | Omprakash S. Kolluri | Multilayer and multifunction vascular graft |
US6333029B1 (en) * | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6361556B1 (en) | 2000-04-27 | 2002-03-26 | Endovascular Tech Inc | System and method for endovascular aneurysm repair in conjuction with vascular stabilization |
US6547820B1 (en) * | 2000-10-03 | 2003-04-15 | Scimed Life Systems, Inc. | High profile fabric graft for arteriovenous access |
US20020084178A1 (en) * | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
US7828833B2 (en) * | 2001-06-11 | 2010-11-09 | Boston Scientific Scimed, Inc. | Composite ePTFE/textile prosthesis |
US20030017775A1 (en) * | 2001-06-11 | 2003-01-23 | Scimed Life Systems. Inc.. | Composite ePTFE/textile prosthesis |
US6926735B2 (en) * | 2002-12-23 | 2005-08-09 | Scimed Life Systems, Inc. | Multi-lumen vascular grafts having improved self-sealing properties |
-
2003
- 2003-04-24 US US10/422,118 patent/US7452374B2/en not_active Expired - Fee Related
-
2004
- 2004-04-22 JP JP2006513212A patent/JP2006524117A/ja active Pending
- 2004-04-22 EP EP04760324A patent/EP1631332A1/en not_active Withdrawn
- 2004-04-22 WO PCT/US2004/012404 patent/WO2004096307A1/en active Application Filing
- 2004-04-22 CA CA002525489A patent/CA2525489A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619641A (en) * | 1984-11-13 | 1986-10-28 | Mount Sinai School Of Medicine Of The City University Of New York | Coaxial double lumen anteriovenous grafts |
EP0492481A1 (en) * | 1990-12-27 | 1992-07-01 | Corvita Corporation | Mesh composite graft |
JP2002522155A (ja) * | 1998-08-14 | 2002-07-23 | ボストン・サイエンティフィク・サイムド・インコーポレーテッド | ステント・グラフト・膜体及びその製造方法 |
JP2003511196A (ja) * | 1999-10-15 | 2003-03-25 | エドワーズ ライフサイエンシーズ コーポレイション | 積層型自己封鎖性血管アクセス移植片 |
JP2004538090A (ja) * | 2001-07-23 | 2004-12-24 | ノボバスキュラー インコーポレーテッド | 酸化窒素放出ePTFEコーティング医療用デバイスサンドイッチ |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018519893A (ja) * | 2015-06-05 | 2018-07-26 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | テーパ付き低出血性植え込み型人工器官 |
JP2020110612A (ja) * | 2015-06-05 | 2020-07-27 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティドW.L. Gore & Associates, Incorporated | テーパ付き低出血性植え込み型人工器官 |
JP7021275B2 (ja) | 2015-06-05 | 2022-02-16 | ダブリュ.エル.ゴア アンド アソシエイツ,インコーポレイティド | テーパ付き低出血性植え込み型人工器官 |
Also Published As
Publication number | Publication date |
---|---|
CA2525489A1 (en) | 2004-11-11 |
US20040215337A1 (en) | 2004-10-28 |
EP1631332A1 (en) | 2006-03-08 |
WO2004096307A1 (en) | 2004-11-11 |
US7452374B2 (en) | 2008-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006524117A (ja) | 手術後に迅速に自らシールする能力を持つ動静脈移植片 | |
JP2939337B2 (ja) | 三次元編組軟組織プロテーゼ | |
US5700287A (en) | Prosthetic vascular graft with deflectably secured fibers | |
EP1796587B1 (en) | Composite vascular graft with antimicrobial and biodegradable matrices and an outer fabric layer | |
TWI766853B (zh) | 經編針織物及醫療材料 | |
US5910168A (en) | Prosthetic vascular graft | |
US5320100A (en) | Implantable prosthetic device having integral patency diagnostic indicia | |
AU676666B2 (en) | Controlled porosity implantable primary lumen device | |
US5192310A (en) | Self-sealing implantable vascular graft | |
JP2006511282A (ja) | 自己シール特性が改良されたマルチ管腔血管グラフト | |
JP2004526472A (ja) | 動静脈アクセスのための高輪郭の布移植片 | |
KR20140132366A (ko) | 향상된 생체적합성 표면 및 이러한 표면을 일체화한 장치 | |
RU2670970C1 (ru) | Сосудистый протез | |
US20210059807A1 (en) | Strong, flexible, and thrombus-free woven nanotextile based vascular grafts, and method of production thereof | |
JP2020536625A (ja) | 可撓性中空管腔複合材料 | |
JP3591868B2 (ja) | 人工補綴物 | |
JPH04250167A (ja) | 医療用補綴材料 | |
JP3766755B2 (ja) | 生体内留置管 | |
Mankodi | Application of textile materials in cardiovascular implants | |
Planck | General Aspects in the use of Medical Textiles for Implantation | |
RU2670671C2 (ru) | Протез сосуда |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060202 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060616 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070411 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070411 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080326 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110221 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110705 |